Telangana already ranks as a leading Asia life sciences hub, with more than 2,000 companies valued around $80 billion, 250+ US FDA-approved manufacturing sites, and about a third of global vaccine output, earning the label 'Vaccine Capital'.

The state hosts operations of global pharma players and accounts for roughly 40% of India’s pharmaceutical production, underpinning its manufacturing prowess.

Green Pharma City will operate under sustainable industrial cluster principles, featuring zero liquid discharge, centralized waste management, and energy-efficient systems.

The policy emphasizes value, innovation, and integration to position Telangana as a global leader in life sciences, underscoring data-led discovery, precision medicine, and advanced therapies.

Hyderabad hosts over 20 life sciences and MedTech incubators, reinforcing Telangana’s status as a premier life sciences hub.

The policy will consolidate manufacturing strengths and accelerate Telangana’s evolution into a globally competitive hub for frontier R&D in life sciences.

The policy aims to showcase Telangana’s innovation ecosystem, foster high-value collaborations, and accelerate progress toward the $250-billion target by 2030.

A central infrastructure focus is the Green Pharma City, with sustainability priorities and a roadmap to lead in manufacturing, R&D, and advanced therapies.

Telangana’s ecosystem includes world-class infrastructure, a cluster-based approach, and a deep talent pool with more than 20 life sciences and MedTech incubators in Hyderabad and across the state.

Telangana plans a $250 billion life sciences economy by 2030 under a new policy to be unveiled by the chief minister at Davos, signaling a bold push to position the state as a global hub.

The Chief Minister envisions Telangana taking a leadership role globally in healthcare and life sciences innovation, backed by the Telangana Global Life Sciences ecosystem as a flagship platform for collaboration and investment.